By Fineline Cube 
UK-based biotech Alchemab Therapeutics Ltd entered into a licensing agreement with US major Eli Lilly & Co. (NYSE: LLY) this week, relating to its ATLX-1282, a first-in-class IND-ready program for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. This transaction builds on a separate discovery collaboration agreement with Lilly announced in January 2025 to discover, develop, and commercialize up to five novel therapeutic candidates for ALS.
Deal Structure and Financial Terms
The transaction is valued at up to a total of USD 415 million, including an undisclosed upfront payment, potential discovery, development, and commercialization payments, and royalties. Under the deal, Alchemab will advance the program through early Phase I clinical trials. Following this, Eli Lilly will lead all further development and commercialization efforts.
Program Overview
ATLX-1282 is a first-in-class program designed to address the unmet needs in the treatment of ALS and other neurodegenerative conditions. This collaboration aims to leverage Alchemab’s innovative approach and Eli Lilly’s expertise in drug development to bring new therapeutic options to patients.-Fineline Info & Tech